About the Company
We do not have any company description for Neumora Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Neumora Therapeutics, Inc.
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861
Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on ...
NMRA - Neumora Therapeutics Inc News | Morningstar
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire Apr 7, 2025 9:45am ...
Neumora Therapeutics, Inc. Sued for Securities Law Violations ...
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire NEW YORK, March 18, 2025 ...
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces ...
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of ...
News provided by Neumora Therapeutics, Inc. Jul 09, 2025, 7:00 AM ET NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions ...
Neumora Therapeutics Reports First Quarter 2025 Financial Results and ...
WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...
Neumora Therapeutics Inc put volume heavy and directionally ... - Nasdaq
Bearish flow noted in Neumora Therapeutics (NMRA) Inc with 8,496 puts trading, or 8x expected. Most active are Jan-25 5 puts and Jan-25 15 calls, with total volume in those strikes near 8,300 ...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 ...
WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...
Neumora Therapeutics Inc trading resumes - Nasdaq
09:39 EST Neumora Therapeutics (NMRA) Inc trading resumesDon't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications ...
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Consensus ...
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings ...
Neumora Therapeutics, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.42 EPS, expectations were $-0.4. Operator: Ladies and gentlemen, thank you for standing by. At this ...
Similar Companies
Loading the latest forecasts...